Loading
A phase 1/2 trial of INV-8989 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer, endometrial cancer and biliary tract cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations is a phase 1/2 interventional study registered as NCT07610798 by Shenzhen Ionova Life Sciences Co., Ltd., with 178 participants planned, started 2026-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: INV-8989.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shenzhen Ionova Life Sciences, Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/